EPHX1 polymorphisms are not associated with warfarin response in an Italian population

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 791-

  Ciccacci, C ^a   Paolillo, N ^a   Di Fusco, D ^a   Novelli, G ^a   Borgiani, P ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; DOSE RESPONSE; GENOTYPE; HUMAN; ITALY; LETTER; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; EPOXIDE HYDROLASES; FEMALE; HUMANS; ITALY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; WARFARIN;

EID: 79956313731     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.31     Document Type: Letter

References (5)

1. Pautas, E. et al. Genetic factors (VKORC1, CYP2C9, EPHX1, And CYP4F2) are predictor variables for warfarin response in very elderly, Frail inpatients. Clin. Pharmacol. Ther. 87, 57-64 (2010).
2. Borgiani, P., Ciccacci, C., Forte, V., Romano, S., Federici, G. & Novelli, G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose efect of warfarin in Italians. Pharmacogenomics 8, 1545-1550 (2007). (Pubitemid 350286398)
3. Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) signifcantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261-266 (2009).
4. Carlquist, J.F. et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J. Thromb. Thrombolysis 30, 358-364 (2010).
5. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).